Evidence map›Paper›PMID 33108255›Full record

ArticleVirulence2020

Shorter incubation period is associated with severe disease progression in patients with COVID-19.

Changxiang Lai, Rentao Yu, Mingbo Wang, Wenjie Xian, Xin Zhao, Qiyuan Tang, Ruikun Chen, Xuan Zhou, Xuan Li, Zhiyu Li and 3 more

Registry-linked trialOpen access · goldAbstract readComparative Study
In one paragraph

Article in Virulence, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04340349 (Low-dose Hydroxychloroquine and Bromhexine), which is not on this map. Cited by 14 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 3 pooled it
0.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04340349 early_phase1unknown statusnot on this mapstarted 2021, after this paper: background citation

Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)

TypeinterventionalSponsorInstituto Nacional de RehabilitacionRan2021 to 2021Enrolled214ConditionsHydroxychloroquine, Antimalarials, Enzyme Inhibitors, Antirheumatic AgentsArmsHydroxychloroquine Sulfate, Bromhexine 8 MG
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Back to basics in COVID-19: Antigens and antibodies-Completing the puzzle.Journal of cellular and molecular medicine · 2021
    Review
  14. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Changxiang LaiDepartment of Liver Diseases, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, the Second Affiliated Hospital of Southern University of Science and Technology , Shenzhen, Guangdong, China.
Rentao YuDepartment of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University) , Chongqing, China.ORCID 0000-0003-4952-9274
Mingbo WangDepartment of Liver Diseases, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, the Second Affiliated Hospital of Southern University of Science and Technology , Shenzhen, Guangdong, China.
Wenjie XianDepartment of Liver Diseases, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, the Second Affiliated Hospital of Southern University of Science and Technology , Shenzhen, Guangdong, China.
Xin ZhaoDepartment of Liver Diseases, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, the Second Affiliated Hospital of Southern University of Science and Technology , Shenzhen, Guangdong, China.
Qiyuan TangDepartment of Liver Diseases, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, the Second Affiliated Hospital of Southern University of Science and Technology , Shenzhen, Guangdong, China.
Ruikun ChenDepartment of Liver Diseases, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, the Second Affiliated Hospital of Southern University of Science and Technology , Shenzhen, Guangdong, China.
Xuan ZhouDepartment of Liver Diseases, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, the Second Affiliated Hospital of Southern University of Science and Technology , Shenzhen, Guangdong, China.
Xuan LiDepartment of Liver Diseases, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, the Second Affiliated Hospital of Southern University of Science and Technology , Shenzhen, Guangdong, China.
Zhiyu LiDepartment of Liver Diseases, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, the Second Affiliated Hospital of Southern University of Science and Technology , Shenzhen, Guangdong, China.
Zhiwei LiDepartment of Hepatobiliary Surgery, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, the Second Affiliated Hospital of Southern University of Science and Technology , Shenzhen, Guangdong, China.
Guohong DengDepartment of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University) , Chongqing, China.
Fang WangDepartment of Liver Diseases, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, the Second Affiliated Hospital of Southern University of Science and Technology , Shenzhen, Guangdong, China.
Southern University of Science and Technology · CNArmy Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The diagnosed COVID-19 cases revealed that the incubation periods (IP) varied a lot among patients. However, few studies had emphasized on the different clinical features and prognosis of patients with different IP. A total of 330 patients with laboratory-confirmed COVID-19 were enrolled and classified into immediate onset group(IP<3 days, I group, 57 cases) and late onset group(IP>10 days, L group, 75 cases) based on IP. The difference of clinical characteristics and prognosis of the two groups were compared. There were more patients with fever in I group than in L group(P = 0.003), and counts of all the total lymphocytes, total T lymphocytes, CD4 + and CD8 + T lymphocytes were significantly different between the two groups(all P < 0.01). Besides, patients in L group had more GGOs in CT scan than I group and there were more patients in I group receiving antibiotic treatment than in L group(P < 0.001). For disease aggravation, the median CT scores were comparable between the two groups, but individually, there were more patients with increased CT score during hospitalization in I group than in L group. The aggravation incidence of CT presentation was 21.1% in I group, significantly higher than L group(8.0%, P = 0.042). Multivariable COX models suggested that IP was the only independent factors for CT aggravation. Conclusively, patients with different IP were different in clinical symptoms, laboratory tests, and CT presentations. Shorter IP was associated with the aggravation of lung involvement in CT scan.

Indexed as

Infectious Disease Incubation PeriodAdultBetacoronavirusCoronavirus InfectionsCOVID-19Disease ProgressionFemaleFeverHospitalizationHumansLymphocyte CountMaleMiddle AgedPandemicsPneumonia, ViralPrognosisCOVID-19CT scoresdisease aggravationincubation periodSARS-CoV-2

Identifiers

PMID33108255
PMCPMC7595588
OpenAlexW3094883178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.